TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen University...
Continue reading

Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Pyrotinib/Capecitabine Effective for HER2-Positive Metastatic Breast Cancer

Pyrotinib, an irreversible pan-ErbB inhibitor, provides an effective treatment option in combination with capecitabine for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, according to results of a phase 3 trial to be presented later this month in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The open-label, multicenter PHOEBE trial enrolled patients with HER2-positive metastatic breast cancer following treatment ...
Continue reading

Sacituzumab Govitecan for TNBC: An Interview With Sara Tolaney, MD, MPH

The FDA recently granted approval to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc) for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Approval was based on a clinical trial (NCT01631552) that enrolled 108 patients with metastatic TNBC. In an interview with i3 Health, Sara Tolaney, MD, MPH, one of the study authors, provides insights on treating TNBC and the significance of the sacituzumab govitecan approval.What are the m...
Continue reading

FDA Grants Approval to Sacituzumab Govitecan-Hziy for TNBC

Accelerated approval was granted to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc), a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Sacituzumab govitecan-hziy works by targeting the Trop-2 receptor, mitigating cancer growth and spread. In addition, this drug is linked to topoisomerase inhibitor, which is a chemical compound toxic to cancer cells."Met...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.